The Effect of Treatment on Circulating Tumor Cells in Bladder Cancer Patients With Muscle-invasive or Advanced Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00829920|
Recruitment Status : Completed
First Posted : January 27, 2009
Last Update Posted : June 25, 2013
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||44 participants|
|Official Title:||The Effect of Treatment on Circulating Tumor Cells in Bladder Cancer Patients With Muscle-invasive or Advanced Disease|
|Study Start Date :||November 2008|
|Actual Primary Completion Date :||November 2012|
|Actual Study Completion Date :||February 2013|
Patients with muscle invasive or metastatic bladder cancer who will be planning for treatment with surgery or chemotherapy.
- Effect of therapy [ Time Frame: baseline and then every 2 months ]To determine the effect of therapy (cystectomy or chemotherapy) on circulating tumor cell (CTC) levels in bladder cancer patients.
- Presence of baseline CTC [ Time Frame: baseline and then every 2 months ]Assess for the presence of baseline CTC in bladder cancer patients with muscle-invasive or metastatic disease.
- Assessing insulin like growth factor [ Time Frame: baseline and then every 2 months ]Determine the feasibility of assessing insulin like growth factor (IGF) I-R and c-Met by FISH in circulating tumor cells of patients with advanced bladder cancer.
- Correlation between CTC levels and clinical outcome [ Time Frame: baseline and then every 2 months ]Evaluate for any potential correlation between CTC levels and clinical outcome
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00829920
|United States, Colorado|
|University of Colorado Hospital|
|Aurora, Colorado, United States, 80010|
|Principal Investigator:||Thomas W. Flaig, MD||University of Colorado, Denver|